Epirubicin Hydrochloride + Ifosfamide + Sorafenib Tosylate
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pleomorphic Rhabdomyosarcoma
Conditions
Pleomorphic Rhabdomyosarcoma, Stage IIB Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7, Stage IV Adult Soft Tissue Sarcoma AJCC v7
Trial Timeline
Dec 3, 2013 → Dec 31, 2020
NCT ID
NCT02050919About Epirubicin Hydrochloride + Ifosfamide + Sorafenib Tosylate
Epirubicin Hydrochloride + Ifosfamide + Sorafenib Tosylate is a phase 2 stage product being developed by Bayer for Pleomorphic Rhabdomyosarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02050919. Target conditions include Pleomorphic Rhabdomyosarcoma, Stage IIB Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02050919 | Phase 2 | Completed |
Competing Products
2 competing products in Pleomorphic Rhabdomyosarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CAB-AXL-ADC + PD-1 inhibitor | BioAtla | Phase 1/2 | 33 |
| Panitumumab | Amgen | Phase 2 | 51 |